1. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes: 2021. Diabetes Care 2021;44(Suppl 1):S15-33.
Article PubMed PDF
2. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006;29:1866-71.
Article PubMed
3. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007;30:677-82.
PubMed
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
Article PubMed
5. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care 1999;26:771-89.
PubMed
6. Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. Diabetes Care 2014;37:3188-95.
Article PubMed PMC
7. Wood GC, Gerhard GS, Benotti P, Petrick AT, Gabrielsen JD, Strodel WE, et al. Preoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis. Ann Surg 2015;261:125-8.
PubMed
8. Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Bottcher A, Sanchez-Garrido MA, et al. Targeted pharmacological therapy restores β-cell function for diabetes remission. Nat Metab 2020;2:192-209.
Article PubMed
9. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
Article PubMed
10. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1:28-34.
Article PubMed
11. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012;308:2489-96.
Article PubMed PMC
12. Zhyzhneuskaya SV, Al-Mrabeh A, Peters C, Barnes A, Aribisala B, Hollingsworth KG, et al. Time course of normalization of functional β-cell capacity in the diabetes remission clinical trial after weight loss in type 2 diabetes. Diabetes Care 2020;43:813-20.
Article PubMed
13. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How do we define cure of diabetes? Diabetes Care 2009;32:2133-5.
Article PubMed PMC
14. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 2021;44:2438-44.
Article PubMed PMC
15. Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 1995;98:75-84.
Article PubMed
16. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 2014;30:96-102.
Article PubMed PMC
17. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-91.
Article PubMed PMC
18. Tayek JA. Is weight loss a cure for type 2 diabetes? Diabetes Care 2002;25:397-8.
Article PubMed
19. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-15.
Article PubMed
20. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781-9.
Article PubMed
21. Hanas R, John G; International HBA1c Consensus Committee. 2010 Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010;33:1903-4.
Article PubMed PMC
22. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018;41:2275-80.
Article PubMed PMC
23. McInnes N, Hall S, Sultan F, Aronson R, Hramiak I, Harris S, et al. Remission of type 2 diabetes following a short-term intervention with insulin glargine, metformin, and dapagliflozin. J Clin Endocrinol Metab 2020;105:dgaa248.
Article PubMed
24. Miras AD, Perez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7:549-59.
Article PubMed
25. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009;32:514-20.
PubMed PMC
26. Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, Camastra S, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 2013;98:4391-9.
Article PubMed
27. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
Article PubMed
28. Purnell JQ, Dewey EN, Laferrere B, Selzer F, Flum DR, Mitchell JE, et al. Diabetes remission status during seven-year follow-up of the longitudinal assessment of bariatric surgery study. J Clin Endocrinol Metab 2021;106:774-88.
Article PubMed
29. Purnell JQ, Selzer F, Wahed AS, Pender J, Pories W, Pomp A, et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. Diabetes Care 2016;39:1101-7.
Article PubMed PMC
30. Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316-23.
Article PubMed PMC
31. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316-23.
Article PubMed
32. Ding SA, Simonson DC, Wewalka M, Halperin F, Foster K, Goebel-Fabbri A, et al. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab 2015;100:2546-56.
Article PubMed PMC
33. Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 2014;149:707-15.
Article PubMed PMC
34. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76.
Article PubMed PMC
35. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240-9.
Article PubMed PMC
36. Halperin F, Ding SA, Simonson DC, Panosian J, Goebel-Fabbri A, Wewalka M, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 2014;149:716-26.
Article PubMed PMC
37. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 2016;59:945-53.
Article PubMed PMC
38. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-85.
Article PubMed
39. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009 122:248-56. e5.
Article PubMed
40. Yu J, Zhou X, Li L, Li S, Tan J, Li Y, et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg 2015;25:143-58.
Article PubMed
41. Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C, et al. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95:4823-43.
Article PubMed
42. Smith MD, Patterson E, Wahed AS, Belle SH, Berk PD, Courcoulas AP, et al. Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. Obes Surg 2011;21:1687-92.
Article PubMed PMC
43. Lupoli R, Lembo E, Saldalamacchia G, Avola CK, Angrisani L, Capaldo B. Bariatric surgery and long-term nutritional issues. World J Diabetes 2017;8:464-74.
Article PubMed PMC
44. Morgan DJ, Ho KM, Platell C. Incidence and determinants of mental health service use after bariatric surgery. JAMA Psychiatry 2020;77:60-7.
Article PubMed
45. Omalu BI, Ives DG, Buhari AM, Lindner JL, Schauer PR, Wecht CH, et al. Death rates and causes of death after bariatric surgery for Pennsylvania residents, 1995 to 2004. Arch Surg 2007 142:923-8. discussion 929.
Article PubMed
46. Kasama K, Mui W, Lee WJ, Lakdawala M, Naitoh T, Seki Y, et al. IFSO-APC consensus statements 2011. Obes Surg 2012;22:677-84.
Article PubMed
47. American Diabetes Association. 7. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes: 2018. Diabetes Care 2018;41(Suppl 1):S65-72.
Article PubMed PDF
48. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017;6:187-94.
Article PubMed PMC
49. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-32.
Article PubMed
50. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-6.
Article PubMed
51. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-602.
PubMed
52. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60.
PubMed
53. Chen A, Huang Z, Wan X, Deng W, Wu J, Li L, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012;35:474-81.
Article PubMed PMC
54. Chon S, Rhee SY, Ahn KJ, Baik SH, Park Y, Nam MS, et al. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: a multicentre randomized trial. Diabetes Obes Metab 2018;20:1121-30.
Article PubMed
55. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care 2011;34:1848-53.
Article PubMed PMC
56. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-12.
Article PubMed PMC
57. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, doubleblind trial. Lancet 2019;394:1519-29.
Article PubMed
58. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-32.
PubMed PMC
59. Leahy JL, Cooper HE, Deal DA, Weir GC. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986;77:908-15.
Article PubMed PMC
60. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
Article PubMed PMC
61. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
Article PubMed
62. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:844-6.
Article PubMed PMC
63. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2007;22:453-8.
Article PubMed PMC
64. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-7.
PubMed PMC
65. De Jesus DF, Kulkarni RN. More is better: combinatorial therapy to restore β-cell function in diabetes. Nat Metab 2020;2:130-1.
Article PubMed
66. Khazrai YM, Buzzetti R, Del Prato S, Cahn A, Raz I, Pozzilli P. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. J Diabetes Complications 2015;29:599-606.
Article PubMed
67. Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA 2016;315:1034-45.
Article PubMed PMC
68. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes: 2021. Diabetes Care 2021;44(Suppl 1):S111-24.
Article PubMed PDF
69. American Diabetes Association. 12. Older adults: standards of medical care in diabetes: 2021. Diabetes Care 2021;44(Suppl 1):S168-79.
Article PubMed PDF
70. American Diabetes Association. 4. Lifestyle management. Diabetes Care 2017;40(Suppl 1):S33-43.
Article PubMed PDF
71. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1985;61:917-25.
Article PubMed
72. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-67.
Article PubMed
73. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104:531-43.
Article PubMed
74. Very low-calorie diets. National task force on the prevention and treatment of obesity, national institutes of health. JAMA 1993;270:967-74.
PubMed
75. Sellahewa L, Khan C, Lakkunarajah S, Idris I. A systematic review of evidence on the use of very low calorie diets in people with diabetes. Curr Diabetes Rev 2017;13:35-46.
Article PubMed
76. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.
Article PubMed PMC
77. Steven S, Taylor R. Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration type 2 diabetes. Diabet Med 2015;32:1149-55.
Article PubMed
78. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, clusterrandomised trial. Lancet 2018;391:541-51.
Article PubMed
79. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2020;8:477-89.
Article PubMed
80. Astrup A, Vrist E, Quaade F. Dietary fibre added to very low calorie diet reduces hunger and alleviates constipation. Int J Obes 1990;14:105-12.
81. Andersen T. Liver and gallbladder disease before and after very-low-calorie diets. Am J Clin Nutr 1992;56(1 Suppl):235S-9S.
Article PubMed
82. Sours HE, Frattali VP, Brand CD, Feldman RA, Forbes AL, Swanson RC, et al. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981;34:453-61.
Article PubMed
83. Tsai AG, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283-93.
Article PubMed
84. Thorell A, MacCormick AD, Awad S, Reynolds N, Roulin D, Demartines N, et al. Guidelines for perioperative care in bariatric surgery: enhanced recovery after surgery (eras) society recommendations. World J Surg 2016;40:2065-83.
Article PubMed
85. Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 2017;26:27-38.
Article PubMed
86. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 2018;41:1801-8.
Article PubMed
87. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016;18:203-16.
Article PubMed PMC
88. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-8.
Article PubMed
89. Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 2021;106:388-96.
Article PubMed
90. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24.
PubMed
91. Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989.
Article PubMed
92. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22.
Article PubMed
93. Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med 2020;173:417-25.
PubMed
94. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014;11:202-30.
Article PubMed
95. Pal A, McCarthy MI. The genetics of type 2 diabetes and its clinical relevance. Clin Genet 2013;83:297-306.
Article PubMed
96. Poulsen P, Vaag AA, Kyvik KO, Moller Jensen D, Beck-Nielsen H. Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia 1997;40:439-46.
Article PubMed
97. Gunderson EP, Hurston SR, Ning X, Lo JC, Crites Y, Walton D, et al. Lactation and progression to type 2 diabetes mellitus after gestational diabetes mellitus: a prospective cohort study. Ann Intern Med 2015;163:889-98.
Article PubMed PMC
98. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001;50 Suppl 1:S154-9.
Article PubMed
99. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Meneur C, Bernal-Mizrachi E. Natural history of β-cell adaptation and failure in type 2 diabetes. Mol Aspects Med 2015;42:19-41.
Article PubMed
100. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 2012;150:1223-34.
Article PubMed PMC
101. Cinti F, Bouchi R, Kim-Muller JY, Ohmura Y, Sandoval PR, Masini M, et al. Evidence of β-cell dedifferentiation in human type 2 diabetes. J Clin Endocrinol Metab 2016;101:1044-54.
Article PubMed
102. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care 2008;31 Suppl 2:S290-6.
PubMed
103. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 2006;9:497-507.
Article PubMed
104. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia 2009;52:2270-6.
Article PubMed
105. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969;123:261-6.
Article PubMed
106. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85.
Article PubMed
107. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care 2013;36:1047-55.
PubMed PMC
108. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab 2018;28:547-56.e3.
Article PubMed
109. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020 158:1999-2014. e1.
Article PubMed
110. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89.
Article PubMed
111. Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016;23:591-601.
Article PubMed PMC
112. Ryan DH. Energy balance and weight loss for diabetes remission. Diabetes Spectr 2020;33:117-24.
Article PubMed PMC
113. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30:2940-4.
Article PubMed
114. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond) 2015;128:405-10.
Article PubMed PDF
115. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019;7:726-36.
Article PubMed
116. Kim ES, Jeong JS, Han K, Kim MK, Lee SH, Park YM, et al. Impact of weight changes on the incidence of diabetes mellitus: a Korean nationwide cohort study. Sci Rep 2018;8:3735.
Article PubMed PMC
117. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis 2013;9:379-84.
Article PubMed
118. Still CD, Wood GC, Benotti P, Petrick AT, Gabrielsen J, Strodel WE, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol 2014;2:38-45.
Article PubMed PMC
119. Aron-Wisnewsky J, Sokolovska N, Liu Y, Comaneshter DS, Vinker S, Pecht T, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia 2017;60:1892-902.
Article PubMed
120. Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg 2017;266:650-7.
PubMed
121. Pucci A, Tymoszuk U, Cheung WH, Makaronidis JM, Scholes S, Tharakan G, et al. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med 2018;35:360-7.
Article PubMed
122. Still CD, Benotti P, Mirshahi T, Cook A, Wood GC. DiaRem
2: incorporating duration of diabetes to improve prediction of diabetes remission after metabolic surgery. Surg Obes Relat Dis 2019;15:717-24.
Article PubMed
123. Guerron AD, Perez JE, Risoli T Jr, Lee HJ, Portenier D, Corsino L. Performance and improvement of the DiaRem score in diabetes remission prediction: a study with diverse procedure types. Surg Obes Relat Dis 2020;16:1531-42.
Article PubMed
124. Kwee LC, Ilkayeva O, Muehlbauer MJ, Bihlmeyer N, Wolfe B, Purnell JQ, et al. Metabolites and diabetes remission after weight loss. Nutr Diabetes 2021;11:10.
Article PubMed PMC
125. Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808-15.
Article PubMed
126. Tangelloju S, Little BB, Esterhay RJ, Brock G, LaJoie AS. Type 2 diabetes mellitus (T2DM) “remission” in non-bariatric patients 65 years and older. Front Public Health 2019;7:82.
Article PubMed PMC
127. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28.
Article PubMed
128. Thom G, Messow CM, Leslie WS, Barnes AC, Brosnahan N, McCombie L, et al. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). Diabet Med 2021;38:e14395.
Article PubMed
129. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2014;2:152-64.
Article PubMed
130. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:344-355.
Article PubMed
131. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365:1597-604.
Article PubMed
132. Taylor R, Barnes AC. Translating aetiological insight into sustainable management of type 2 diabetes. Diabetologia 2018;61:273-83.
Article PubMed
133. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-5.
PubMed
134. Folz R, Laiteerapong N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 2021;64:2131-7.
Article PubMed PMC
135. Ihnat MA, Thorpe JE, Ceriello A. Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 2007;24:582-6.
Article PubMed
136. Prattichizzo F, de Candia P, De Nigris V, Nicolucci A, Ceriello A. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism 2020;110:154308.
Article PubMed
137. Oh SH, Ku H, Park KS. Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a populationbased study using administrative data. BMC Public Health 2021;21:548.
Article PubMed PMC
138. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8.
Article PubMed
139. Atienza AA, King AC. Community-based health intervention trials: an overview of methodological issues. Epidemiol Rev 2002;24:72-9.
Article PubMed
140. Brownell KD, Frieden TR. Ounces of prevention: the public policy case for taxes on sugared beverages. N Engl J Med 2009;360:1805-8.
Article PubMed
141. Rhee EJ. Diabetes in Asians. Endocrinol Metab (Seoul) 2015;30:263-9.
Article PubMed PMC
142. Kelly J, Karlsen M, Steinke G. Type 2 diabetes remission and lifestyle medicine: a position statement from the American College of Lifestyle Medicine. Am J Lifestyle Med 2020;14:406-19.
Article PubMed PMC
143. Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-76.
Article PubMed PMC
144. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-92.
Article PubMed PMC
145. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a metaanalysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431-7.
Article PubMed
146. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
Article PubMed PMC
147. Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive glucose control in patients with type 2 diabetes: 15-year follow-up. N Engl J Med 2019;380:2215-24.
Article PubMed PMC